Vergleich

WT1 317-327 (HLA-A*01:01) Europäischer Partner

58,00 €
Zzgl. MwSt.
ArtNr EP11465_1
Hersteller peptides & elephants
Menge 1 mg
Kategorie
Typ Peptides
Applikationen IHC
Specific against Human (Homo sapiens)
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Alias TSEKRPFMCAY Wilms-Tumor-Protein HLA-A*01:01 AIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate c
Lieferbar
Description
Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.
The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy.

This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described.Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.
The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy.

This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described.Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.
The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy.

This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described.Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.
The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy.

This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described.Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.
The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy.

This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described.
Keywords
TSEKRPFMCAY Wilms-Tumor-Protein HLA-A*01:01 AIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate c
Sequence
TSEKRPFMCAY
N-Terminus
H
C-Terminus
OH
Purity
0, 95
Counter-Ion
TFA
Protein
Wilms-Tumor-Protein
Gene
WT1
Allele
HLA-A*01:01
Application
Cellular immune response, Immune monitoring, T-cell assays, Immunohistochemistry
Indication
AIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1
Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1
Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1
Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1
Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1
Delivery Time: 10-12 days
Storage
Store dry at -20°C

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 1 mg
Lieferbar: In stock
Listenpreis: 58,00 €
Preis: 58,00 €
lieferbar

Lieferung vsl. bis 18.09.2025 

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen